634 related articles for article (PubMed ID: 30240537)
21. A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome.
Gao F; Pan X; Dodd-Eaton EB; Recio CV; Montierth MD; Bojadzieva J; Mai PL; Zelley K; Johnson VE; Braun D; Nichols KE; Garber JE; Savage SA; Strong LC; Wang W
Genome Res; 2020 Aug; 30(8):1170-1180. PubMed ID: 32817165
[TBL] [Abstract][Full Text] [Related]
22.
da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
[No Abstract] [Full Text] [Related]
23. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
[TBL] [Abstract][Full Text] [Related]
24. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
25. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
[TBL] [Abstract][Full Text] [Related]
26. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
[TBL] [Abstract][Full Text] [Related]
28. Functional characterization of novel germline TP53 variants in Swedish families.
Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
[TBL] [Abstract][Full Text] [Related]
30. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
31. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Arcand SL; Maugard CM; Ghadirian P; Robidoux A; Perret C; Zhang P; Fafard E; Mes-Masson AM; Foulkes WD; Provencher D; Narod SA; Tonin PN
Breast Cancer Res Treat; 2008 Apr; 108(3):399-408. PubMed ID: 17541742
[TBL] [Abstract][Full Text] [Related]
32. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
33. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
[No Abstract] [Full Text] [Related]
34. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing.
Fortuno C; Pesaran T; Mester J; Dolinsky J; Yussuf A; McGoldrick K; James PA; Spurdle AB
Cancer Genet; 2020 Oct; 248-249():11-17. PubMed ID: 32966936
[TBL] [Abstract][Full Text] [Related]
35. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
[TBL] [Abstract][Full Text] [Related]
36. Inherited TP53 Variants and Risk of Prostate Cancer.
Maxwell KN; Cheng HH; Powers J; Gulati R; Ledet EM; Morrison C; Le A; Hausler R; Stopfer J; Hyman S; Kohlmann W; Naumer A; Vagher J; Greenberg SE; Naylor L; Laurino M; Konnick EQ; Shirts BH; AlDubayan SH; Van Allen EM; Nguyen B; Vijai J; Abida W; Carlo MI; Dubard-Gault M; Lee DJ; Maese LD; Mandelker D; Montgomery B; Morris MJ; Nicolosi P; Nussbaum RL; Schwartz LE; Stadler Z; Garber JE; Offit K; Schiffman JD; Nelson PS; Sartor O; Walsh MF; Pritchard CC
Eur Urol; 2022 Mar; 81(3):243-250. PubMed ID: 34863587
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population.
Cao AY; Jin W; Shi PC; Di GH; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2010 Jan; 119(2):295-303. PubMed ID: 19238535
[TBL] [Abstract][Full Text] [Related]
38. Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome.
Subasri V; Light N; Kanwar N; Brzezinski J; Luo P; Hansford JR; Cairney E; Portwine C; Elser C; Finlay JL; Nichols KE; Alon N; Brunga L; Anson J; Kohlmann W; de Andrade KC; Khincha PP; Savage SA; Schiffman JD; Weksberg R; Pugh TJ; Villani A; Shlien A; Goldenberg A; Malkin D
Cancer Res Commun; 2023 May; 3(5):738-754. PubMed ID: 37377903
[TBL] [Abstract][Full Text] [Related]
39. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
[TBL] [Abstract][Full Text] [Related]
40. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
